-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate cost of goods produced and sold and services rendered during the reporting period.
-
Summary
-
Akebia Therapeutics, Inc. quarterly/annual Cost of Revenue history and growth rate from Q4 2018 to Q2 2024.
- Akebia Therapeutics, Inc. Cost of Revenue for the quarter ending June 30, 2024 was $17M, a 1.37% decline year-over-year.
- Akebia Therapeutics, Inc. Cost of Revenue for the twelve months ending June 30, 2024 was $65.3M, a 10.6% decline year-over-year.
- Akebia Therapeutics, Inc. annual Cost of Revenue for 2023 was $74.1M, a 13.3% decline from 2022.
- Akebia Therapeutics, Inc. annual Cost of Revenue for 2022 was $85.6M, a 43.2% decline from 2021.
- Akebia Therapeutics, Inc. annual Cost of Revenue for 2021 was $151M, a 49.2% decline from 2020.
Cost of Revenue, Trailing 12 Months (USD)
Cost of Revenue, Quarterly (USD)
Cost of Revenue, YoY Quarterly Growth (%)